Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Hemodialysis Patients Who Are Receiving Supplemental EPO Therapy

NCT00233597 is registered in ClinicalTrials.gov with AMAG Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00233597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00233597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Hemodialysis Patients Who Are Receiving Supplemental EPO Therapy
Lead sponsor
AMAG Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2004
Completion date
March 31, 2007
Enrollment
230
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

anemia